Sort
17,054 grants matching “genome editing”
iPSC-based blood regenerative therapies for AIDS
$627,832Igor I Slukvin · University Of Wisconsin-Madison · R01 · FY2014 · HL
Long-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIV
$627,757Wenhui Hu · Temple Univ Of The Commonwealth · R01 · FY2022 · DA
Mechanisms of Eph/Ephrin signaling in craniofacial morphogenesis and craniofrontonasal syndrome
$627,714Jeffrey Ohmann Bush · University Of California, San Francisco · R01 · FY2019 · DE
Macrophages and attenuation of inflammation resolution in APOL1 nephropathy
$627,589Jennie J Lin · Northwestern University At Chicago · R01 · FY2023 · DK
Defining cell types, lineage, and connectivity in developing human fetal cortex
$627,560Daniel H Geschwind · University Of California Los Angeles · U01 · FY2015 · MH
Collaborative Research: Mechanisms Underlying Circatidal Rhythms in Parhyale Hawaiensis
$627,543Joshua J Rosenthal · Marine Biological Laboratory · · FY2022 · BIO
Capturing the phenotypic landscape of single-nucleotide variation via systematic genome editing
$627,527Lars M Steinmetz · Stanford University · R01 · FY2021 · GM
Capturing the phenotypic landscape of single-nucleotide variation via systematic genome editing
$627,527Lars M Steinmetz · Stanford University · R01 · FY2020 · GM
Capturing the phenotypic landscape of single-nucleotide variation via systematic genome editing
$627,527Robert St.onge · Stanford University · R01 · FY2018 · GM
Capturing the phenotypic landscape of single-nucleotide variation via systematic genome editing
$627,527Robert St.onge · Stanford University · R01 · FY2019 · GM
Regulatory T Cells and Pulmonary Hypertension
$627,446Mark Robert Nicolls · Palo Alto Veterans Instit For Research · R01 · FY2022 · HL
Probing the Role of Integrator in Neuronal Function
$627,436Eric J Wagner · University Of Rochester · R01 · FY2024 · NS
Systems Control of Normal Aging and Alzheimer's Disease
$627,323Catherine Cook Kaczorowski · Jackson Laboratory · R01 · FY2021 · AG
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation
$627,238Korkut Uygun · Massachusetts General Hospital · R01 · FY2025 · EB
Identification of Genetic and Molecular Bases of Derived Phenotypes in Primate Brain Development
$627,225Nenad Sestan · Yale University · R01 · FY2020 · HG
Developing gene editing platforms for retinal degeneration.
$627,134Gaurav Sahay · Oregon State University · R01 · FY2023 · EY
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** PRRSV IS ONE OF THE MOST IMPORTANT SWINE VIRAL PATHOGENS. THE VIRUS MAINLY INFECTS PORCINE ALVEOLAR MACROPHAGES (PAMS). CD163 IS THE KEY CELLULAR RECEPTOR FOR THE VIRUS ENTRY INTO PAMS AND THE VIRAL MINOR GLYCOPROTEINS GP2 AND GP4 HAVE BEEN SHOWN TO INTERACT WITH CD163. IN VITRO, PRRSV IS MAINLY PROPAGATED IN MARC-145, THE MONKEY EPITHELIAL KIDNEY CELL LINE. CELLULAR FACTORS REQUIRED FOR PRODUCTIVE PRRSV INFECTION ARE NOT FULLY UNDERSTOOD. WE RECENTLY DISCOVERED A SINGLE AMINO ACID RESIDUE IN GP2 THAT DIFFERENTIATES PRRSV INFECTIVITY IN MARC-145 AND PAMS. PARTICULARLY, WILD-TYPE PRRSV CARRYING A LYSINE RESIDUE AT POSITION 160 (K160) IN GP2 REPLICATES EFFICIENTLY IN BOTH MARC-145 AND PAMS WHILEPRRSV MUTANTS CARRYING AN ISOLEUCINE RESIDUE AT POSITION 160 (I160) IN GP2 ONLY INFECTS MARC-145 CELLS BUT NOT PAMS. WE HYPOTHESIZE THAT THERE MIGHT BE UNIDENTIFIED CELLULAR FACTORS THAT CONTROL PRRSV REPLICATION IN THESE TWO DIFFERENT CELL TYPES. TO DEMONSTRATE THIS HYPOTHESIS, WE PROPOSE THREE OBJECTIVES. OBJECTIVES 1: COMPARATIVE ANALYSIS OF PRRSV ENTRY PATHWAYS INTO DIFFERENT CELL TYPES. OBJECTIVE 2: IDENTIFY ADDITIONAL CELLULAR FACTORS REQUIRED FOR PRRSV INFECTION. OBJECTIVE 3: DETERMINE THE POTENTIAL ALTERNATIVE CELLULAR TARGETS FOR PRRSV REPLICATION IN PIGS. KNOWLEDGE GAINED FROM THIS STUDY WILL BE CRITICAL FOR THE RATIONALE DEVELOPMENT OF SAFE AND EFFICACIOUS PRRSV VACCINE. ADDITIONALLY, THIS KNOWLEDGE WILL PROVIDE NOVEL INSIGHTS FOR THE GENERATION OF PRRSV RESISTANT PIGS, EITHER THOUGHT NATURAL SELECTION OR GENOME-EDITING.
$627,000Board Of Regents Of The University Of Nebraska · · FY2023 · National Institute of Food and Agriculture
Novel grafted terpolymers for targeted delivery of CRISPR/Cas9- mediated precise genome editing to the brain
$626,995Jiangbing Zhou · Yale University · UG3 · FY2022 · NS
The CD226 costimulatory axis in type 1 diabetes
$626,917Todd Michael Brusko · University Of Florida · R01 · FY2023 · DK
IDENTIFICATION OF COMMON AND UNCOMMON GENE VARIANTS IN PBC
$626,764Michael F. Seldin · University Of California At Davis · R01 · FY2012 · DK
The Pathogenesis of RNA Splicing Factor Retinitis Pigmentosa
$626,663Eric A Pierce · Massachusetts Eye And Ear Infirmary · R01 · FY2015 · EY
Molecular Mechanisms of TRIB1 Regulation of Hepatic Metabolism
$626,624Robert Clayton Bauer · Columbia University Health Sciences · R01 · FY2023 · DK
REST and Neural Network Dysfunction in Alzheimer's Disease
$626,369Bruce A Yankner · Harvard Medical School · R56 · FY2020 · AG
Binding of Epstein Barr Virus EBNA2 Unifies Multiple Sclerosis Genetic Mechanisms
$626,014Matthew Tyson Weirauch · Cincinnati Childrens Hosp Med Ctr · R01 · FY2025 · NS
Emerging multidrug resistance mechanisms in Campylobacter
$626,007Qijing Zhang · Iowa State University · R01 · FY2024 · AI